A detailed history of Prestige Wealth Management Group LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Prestige Wealth Management Group LLC holds 14 shares of HALO stock, worth $721. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14
Holding current value
$721
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 26, 2024

BUY
$33.68 - $41.95 $471 - $587
14 New
14 $0
Q3 2023

Apr 26, 2024

SELL
$36.46 - $44.03 $218 - $264
-6 Reduced 42.86%
8 $0
Q3 2023

Nov 13, 2023

BUY
$36.46 - $44.03 $291 - $352
8 New
8 $0
Q4 2022

Feb 07, 2023

BUY
$40.06 - $59.44 $2,003 - $2,972
50 New
50 $2,000
Q4 2021

Feb 15, 2022

SELL
$31.82 - $40.75 $381 - $489
-12 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$38.47 - $46.42 $461 - $557
12 New
12 $0

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.18B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Prestige Wealth Management Group LLC Portfolio

Follow Prestige Wealth Management Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prestige Wealth Management Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prestige Wealth Management Group LLC with notifications on news.